A noninvasive test for colon cancer may soon be available. A noninvasive stool DNA test for colorectal cancer screening detected significantly more cancers than a commonly used fecal immunochemical test (FIT), according to a study in the April 3 New England Journal of Medicine. Both tests were compared with colonoscopy in 9,989 asymptomatic people 50 to 84 years old at average risk for colorectal cancer. Colonoscopy detected cancer in 65 people, and 60 had stage I, II, or III tumors. The stool DNA test identified 92% of the cancers, including 93% at stages I to III. The overall sensitivity of the FIT was 73.8%. The DNA test measures human hemoglobin and certain cancer-specific mutations. An expert panel at the Food and Drug Administration recommended approval of the test, called Cologuard, on March 28.